- Alkermes recently reported that data from its Phase 2 Vibrance-1 study of oral orexin 2 receptor agonist alixorexton in adults with narcolepsy type 1 were published in The Lancet Neurology, showing statistically significant improvements in wakefulness, excessive daytime sleepiness, and cataplexy versus placebo with a generally well-tolerated safety profile.
- The positive Phase 2 results have already led Alkermes to launch a global Phase 3 Brilliance program in narcolepsy and secured both Breakthrough Therapy and Orphan Drug designations for alixorexton, underscoring its potential importance in hypersomnolence disorders.
- We’ll now examine how the Vibrance-1 results and Phase 3 Brilliance launch might reshape Alkermes’ orexin-focused investment narrative.
AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Alkermes Investment Narrative Recap
To own Alkermes, you need to believe that its orexin portfolio, led by alixorexton, can grow into a meaningful new pillar alongside Vivitrol, Aristada, and Lybalvi, while the company manages rising R&D and some one off revenue benefits. The Vibrance-1 publication strengthens the credibility of alixorexton as a late stage asset and supports the Phase 3 Brilliance program, but the key near term catalyst and risk still center on whether those Phase 3 trials reproduce the Phase 2 efficacy and safety profile.
The most relevant recent announcement here is Alkermes’ launch of the global Phase 3 Brilliance studies in narcolepsy type 1 and type 2 earlier this year, since Vibrance-1 now provides peer reviewed evidence that underpins those trials. Together with Breakthrough Therapy and Orphan Drug designations, this pairing of Phase 2 data and Phase 3 initiation highlights how much of the company’s future value investors are implicitly tying to the success or failure of alixorexton in these pivotal studies.
But while the Brilliance data could be a turning point, investors should also be aware that ...
Read the full narrative on Alkermes (it's free!)
Alkermes' narrative projects $2.3 billion revenue and $374.7 million earnings by 2029. This requires 10.6% yearly revenue growth and about a $308.6 million earnings increase from $66.1 million today.
Uncover how Alkermes' forecasts yield a $56.00 fair value, a 14% upside to its current price.
Exploring Other Perspectives
Before this news, the most optimistic analysts were already modeling revenue of about US$2.8 billion and earnings near US$951.5 million by 2029, so if you lean toward that view, the Vibrance 1 publication might reinforce your confidence in alixorexton’s potential while also reminding you how differently others can assess the same risk that a late stage failure could severely hit those forecasts.
Explore 5 other fair value estimates on Alkermes - why the stock might be worth 22% less than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Alkermes research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Alkermes research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alkermes' overall financial health at a glance.
Contemplating Other Strategies?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
- Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
- Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com